Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 654727, 9 pages
http://dx.doi.org/10.1155/2014/654727
Research Article

IDH1/IDH2 but Not TP53 Mutations Predict Prognosis in Bulgarian Glioblastoma Patients

1Molecular Medicine Center, Medical University of Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria
2Department of Medical Chemistry and Biochemistry, Medical Faculty, Medical University of Sofia, 2 Zdrave Street, 1431 Sofia, Bulgaria
3Department of Neurosurgery, University Multiprofile Hospital for Active Treatment and Emergency Medicine “N.I.Pirogov”, 21 Totleben Boulevard, 1606 Sofia, Bulgaria
4Department of Pathology, University Multiprofile Hospital for Active Treatment and Emergency Medicine “N.I.Pirogov”, 21 Totleben Boulevard, 1606 Sofia, Bulgaria

Received 20 February 2014; Accepted 29 March 2014; Published 24 April 2014

Academic Editor: Eiichi Ishikawa

Copyright © 2014 Gergana Stancheva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Wager, P. Menei, J. Guilhot et al., “Prognostic molecular markers with no impact on decision-making: the paradox of gliomas based on a prospective study,” The British Journal of Cancer, vol. 98, no. 11, pp. 1830–1838, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. F. B. Furnari, T. Fenton, R. M. Bachoo et al., “Malignant astrocytic glioma: genetics, biology, and paths to treatment,” Genes and Development, vol. 21, no. 21, pp. 2683–2710, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. TCGA, “Comprehensive genomic characterization defines human glioblastoma genes and core pathways,” Nature, vol. 455, no. 7216, pp. 1061–1068, 2008. View at Publisher · View at Google Scholar
  4. F. Ducray, S. E. Hallani, and A. Idbaih, “Diagnostic and prognostic markers in gliomas,” Current Opinion in Oncology, vol. 21, no. 6, pp. 537–542, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. D. Krex, B. Klink, C. Hartmann et al., “Long-term survival with glioblastoma multiforme,” Brain, vol. 130, no. 10, pp. 2596–2606, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Weller, J. Felsberg, C. Hartmann et al., “Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German glioma network,” Journal of Clinical Oncology, vol. 27, no. 34, pp. 5743–5750, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. D. W. Parsons, S. Jones, X. Zhang et al., “An integrated genomic analysis of human glioblastoma multiforme,” Science, vol. 321, no. 5897, pp. 1807–1812, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. N. K. Kloosterhof, L. B. Bralten, H. J. Dubbink, P. J. French, and M. J. van den Bent, “Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?” The Lancet Oncology, vol. 12, no. 1, pp. 83–91, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. X. Xu, J. Zhao, Z. Xu et al., “Structures of human cytosolic NADP-dependent isocitrate dehydrogenase reveal a novel self-regulatory mechanism of activity,” The Journal of Biological Chemistry, vol. 279, no. 32, pp. 33946–33957, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Yang, C. Zhong, Y. Peng, Z. Lai, and J. Ding, “Molecular mechanisms of off-on switch of activities of human IDH1 by tumor-associated mutation R132H,” Cell Research, vol. 20, no. 11, pp. 1188–1200, 2010. View at Publisher · View at Google Scholar · View at Scopus
  11. F. E. Bleeker, S. Lamba, S. Leenstra et al., “IDH1 mutations at residue p.R132 (IDH1R132) occur frequently in high-grade gliomas but not in other solid tumors,” Human Mutation, vol. 30, no. 1, pp. 7–11, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Dang, S. Jin, and S. M. Su, “IDH mutations in glioma and acute myeloid leukemia,” Trends in Molecular Medicine, vol. 16, no. 9, pp. 392–397, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Balss, J. Meyer, W. Mueller, A. Korshunov, C. Hartmann, and A. von Deimling, “Analysis of the IDH1 codon 132 mutation in brain tumors,” Acta Neuropathologica, vol. 116, no. 6, pp. 597–602, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Ichimura, D. M. Pearson, S. Kocialkowski et al., “IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas,” Neuro-Oncology, vol. 11, no. 4, pp. 341–347, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Toedt, S. Barbus, M. Wolter et al., “Molecular signatures classify astrocytic gliomas by IDH1 mutation status,” International Journal of Cancer, vol. 128, no. 5, pp. 1095–1103, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. A. von Deimling, A. Korshunov, and C. Hartmann, “The next generation of glioma biomarkers: MGMT methylation, BRAF fusions and IDH1 mutations,” Brain Pathology, vol. 21, no. 1, pp. 74–87, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. H. Yan, D. W. Parsons, G. Jin et al., “IDH1 and IDH2 mutations in gliomas,” The New England Journal of Medicine, vol. 360, no. 8, pp. 765–773, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. H. J. Dubbink, W. Taal, R. van Marion et al., “IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide,” Neurology, vol. 73, no. 21, pp. 1792–1795, 2009. View at Publisher · View at Google Scholar · View at Scopus
  19. M. J. Riemenschneider, J. W. M. Jeuken, P. Wesseling, and G. Reifenberger, “Molecular diagnostics of gliomas: state of the art,” Acta Neuropathologica, vol. 120, no. 5, pp. 567–584, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. Sanson, Y. Marie, S. Paris et al., “Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas,” Journal of Clinical Oncology, vol. 27, no. 25, pp. 4150–4154, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. N. A. Butowski and S. M. Chang, “Glial tumors: the current state of scientific knowledge,” Clinical Neurosurgery, vol. 53, pp. 106–113, 2006. View at Google Scholar · View at Scopus
  22. T. Soussi and K. G. Wiman, “Shaping genetic alterations in human cancer: the p53 mutation paradigm,” Cancer Cell, vol. 12, no. 4, pp. 303–312, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. H. Ohgaki and P. Kleihues, “Genetic alterations and signaling pathways in the evolution of gliomas,” Cancer Science, vol. 100, no. 12, pp. 2235–2241, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. J. R. Hill, N. Kuriyama, H. Kuriyama, and M. A. Israel, “Molecular genetics of brain tumors,” Archives of Neurology, vol. 56, no. 4, pp. 439–441, 1999. View at Google Scholar · View at Scopus
  25. G. Tabatabai, R. Stupp, M. J. Van Den Bent et al., “Molecular diagnostics of gliomas: the clinical perspective,” Acta Neuropathologica, vol. 120, no. 5, pp. 585–592, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Ohgaki and P. Kleihues, “Genetic pathways to primary and secondary glioblastoma,” The American Journal of Pathology, vol. 170, no. 5, pp. 1445–1453, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. D. N. Louis, H. Ohgaki, O. D. Wiestler et al., “The 2007 WHO classification of tumours of the central nervous system,” Acta Neuropathologica, vol. 114, no. 2, pp. 97–109, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Hartmann, J. Meyer, J. Balss et al., “Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas,” Acta Neuropathologica, vol. 118, no. 4, pp. 469–474, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. M. J. van den Bent, H. J. Dubbink, Y. Marie et al., “IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European organization for research and treatment of cancer brain tumor group,” Clinical Cancer Research, vol. 16, no. 5, pp. 1597–1604, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Zhao, Y. Lin, W. Xu et al., “Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1α,” Science, vol. 324, no. 5924, pp. 261–265, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Dang, D. W. White, S. Gross et al., “Cancer-associated IDH1 mutations produce 2-hydroxyglutarate,” Nature, vol. 462, no. 7274, pp. 739–744, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Lu, P. S. Ward, G. S. Kapoor et al., “IDH mutation impairs histone demethylation and results in a block to cell differentiation,” Nature, vol. 483, no. 7390, pp. 474–478, 2012. View at Publisher · View at Google Scholar · View at Scopus
  33. H. Noushmehr, D. J. Weisenberger, K. Diefes et al., “Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma,” Cancer Cell, vol. 17, no. 5, pp. 510–522, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Turcan, D. Rohle, A. Goenka et al., “IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype,” Nature, vol. 483, no. 7390, pp. 479–483, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. G. Jin, Z. J. Reitman, C. G. Duncan et al., “Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas,” Cancer Research, vol. 73, no. 2, pp. 496–501, 2013. View at Publisher · View at Google Scholar
  36. R. Gupta, S. Flanagan, C. C. Li et al., “Expanding the spectrum of IDH1 mutations in gliomas,” Modern Pathology, vol. 26, no. 5, pp. 619–625, 2013. View at Publisher · View at Google Scholar
  37. Y. Zhang, H. Wei, M. Wang et al., “Some novel features of IDH1-mutated acute myeloid leukemia revealed in Chinese patients,” Leukemia Research, vol. 35, no. 10, pp. 1301–1306, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. A. K. Murugan, E. Bojdani, and M. Xing, “Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer,” Biochemical and Biophysical Research Communications, vol. 393, no. 3, pp. 555–559, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. G. Jin, Z. J. Reitman, I. Spasojevic et al., “2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP+-dependent isocitrate dehydrogenase mutations,” PLoS ONE, vol. 6, no. 2, Article ID e16812, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. P. S. Ward, J. Patel, D. R. Wise et al., “The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting α-ketoglutarate to 2-hydroxyglutarate,” Cancer Cell, vol. 17, no. 3, pp. 225–234, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. Y. Sonoda, T. Kumabe, T. Nakamura et al., “Analysis of IDH1 and IDH2 mutations in Japanese glioma patients,” Cancer Science, vol. 100, no. 10, pp. 1996–1998, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Takano, Y. Kato, T. Yamamoto et al., “Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors,” Journal of Neuro-Oncology, vol. 108, no. 3, pp. 361–373, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. F. E. Bleeker, N. A. Atai, S. Lamba et al., “The prognostic IDH1R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma,” Acta Neuropathologica, vol. 119, no. 4, pp. 487–494, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. J. P. Hemerly, A. U. Bastos, and J. M. Cerutti, “Identification of several novel non-p.R132 IDH1 variants in thyroid carcinomas,” European Journal of Endocrinology, vol. 163, no. 5, pp. 747–755, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. K. Wagner, F. Damm, G. Göhring et al., “Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor,” Journal of Clinical Oncology, vol. 28, no. 14, pp. 2356–2364, 2010. View at Publisher · View at Google Scholar · View at Scopus
  46. C. Hartmann, B. Hentschel, W. Wick et al., “Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas,” Acta Neuropathologica, vol. 120, no. 6, pp. 707–718, 2010. View at Publisher · View at Google Scholar · View at Scopus